Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab vs High-Dose Interferon Alfa-2b in Resected High-Risk Melanoma
NCT01274338Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2011
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of ipilimumab in melanoma, sponsored by National Cancer Institute. Started Jun 2011; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01274338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01274338.